Polaryx Therapeutics (FRA:1V8) Total Operating Expense: €4.07 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1V8 Polaryx Therapeutics Inc FRA:1V8
13 GF Score
Price €1.78
View Full Analysis

What is Polaryx Therapeutics Total Operating Expense?

Polaryx Therapeutics FRA:1V8 -7.88% 13 Total Operating Expense is €4.07 Mil as of Mar. 2026. GuruFocus rates FRA:1V8 with a GF Score™ of 13/100.

Polaryx Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was €1.69 Mil. Polaryx Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €4.07 Mil.

Polaryx Therapeutics Total Operating Expense Related Terms

Polaryx Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics Total Operating Expense Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Operating Expense
3.47 4.16 6.68

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.67 0.77 0.83 0.78 1.69
FRA:1V8
13GF Score
Polaryx Therapeutics Inc FRA:1V8
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €4.07 Mil mean?
Polaryx Therapeutics (FRA:1V8) has a Total Operating Expense of €4.07 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' Total Operating Expense too high?
Polaryx Therapeutics' current Total Operating Expense is €4.07 Mil. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' Total Operating Expense compare to ?
Polaryx Therapeutics' Total Operating Expense of €4.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current Total Operating Expense is €4.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (FRA:1V8) has a current Total Operating Expense of €4.07 Mil. The current Total Operating Expense is €4.07 Mil. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Polaryx Therapeutics (FRA:1V8), the current Total Operating Expense is €4.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Comparable Companies
Other Exchanges PLYX:USA
Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for FRA:1V8

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.78
Price